Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24

Benzinga · 4d ago
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.